Deep learning methods have been widely used for various glioma predictions. However, they are usually task-specific, segmentation-dependent and lack of interpretable biomarkers. How to accurately predict the glioma histological grade and molecular subtypes at the same time and provide reliable imaging biomarkers is still challenging. To achieve this, we propose a novel cooperative multi-task learning network (CMTLNet) which consists of a task-common feature extraction (CFE) module, a task-specific unique feature extraction (UFE) module and a unique-common feature collaborative classification (UCFC) module. In CFE, a segmentation-free tumor feature perception (SFTFP) module is first designed to extract the tumor-aware features in a classification manner rather than a segmentation manner. Following that, based on the multi-scale tumor-aware features extracted by SFTFP module, CFE uses convolutional layers to further refine these features, from which the task-common features are learned. In UFE, based on orthogonal projection and conditional classification strategies, the task-specific unique features are extracted. In UCFC, the unique and common features are fused with an attention mechanism to make them adaptive to different glioma prediction tasks. Finally, deep features-guided interpretable radiomic biomarkers for each glioma prediction task are explored by combining SHAP values and correlation analysis. Through the comparisons with recent reported methods on a large multi-center dataset comprising over 1800 cases, we demonstrated the superiority of the proposed CMTLNet, with the mean Matthews correlation coefficient in validation and test sets improved by (4.1%, 10.7%), (3.6%, 23.4%), and (2.7%, 22.7%) respectively for glioma grading, 1p/19q and IDH status prediction tasks. In addition, we found that some radiomic features are highly related to uninterpretable deep features and that their variation trends are consistent in multi-center datasets, which can be taken as reliable imaging biomarkers for glioma diagnosis. The proposed CMTLNet provides an interpretable tool for glioma multi-task prediction, which is beneficial for glioma precise diagnosis and personalized treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.media.2024.103435 | DOI Listing |
Sci Rep
January 2025
Neurology Unit, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Astrocytoma is a common type of glioma and a frequent cause of brain tumour-related epilepsy. Although the link between glioma and epilepsy is well established, the precise mechanisms underlying epileptogenesis in astrocytoma remain poorly understood. In this study, we performed proteomic analysis of astrocytoma tissue from patients with and without seizures using mass spectrometry-based techniques.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Neurological Care Unit, The First Affiliated Hospital of YangTze University, Jingzhou, Hubei, China.
Background: Recent years have seen persistently poor prognoses for glioma patients. Therefore, exploring the molecular subtyping of gliomas, identifying novel prognostic biomarkers, and understanding the characteristics of their immune microenvironments are crucial for improving treatment strategies and patient outcomes.
Methods: We integrated glioma datasets from multiple sources, employing Non-negative Matrix Factorization (NMF) to cluster samples and filter for differentially expressed metabolic genes.
NMR Biomed
March 2025
Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
Hemodynamic measurements such as cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) can provide useful information for the diagnosis and characterization of brain tumors. Previous work showed that arterial spin labeling (ASL) in combination with vasoactive stimulation enabled simultaneous non-invasive evaluation of both parameters, however this approach had not been previously tested in tumors. The aim of this work was to investigate the application of this technique, using a pseudo-continuous ASL (PCASL) sequence combined with breath-holding at 3 T, to measure CBF and CVR in high-grade gliomas and metastatic lesions, and to explore differences across tumoral-peritumoral regions and tumor types.
View Article and Find Full Text PDFCancer J
January 2025
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
There is major interest in deintensifying therapy for isocitrate dehydrogenase-mutant low-grade gliomas, including with single-agent cytostatic isocitrate dehydrogenase inhibitors. These efforts need head-to-head comparisons with proven modalities, such as chemoradiotherapy. Ongoing clinical trials now group tumors by intrinsic molecular subtype, rather than classic clinical risk factors.
View Article and Find Full Text PDFCancer J
January 2025
From the Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
There has been a significant paradigm shift in the clinical management of lower-grade glioma patients given the recent updates to the 2021 World Health Organization classification along with long-term results from randomized phase III clinical trials. As a result, we are now better able to diagnose and assign patients to the most appropriate treatment course. This review provides a comprehensive summary of the most robust and reliable molecular biomarkers for adult lower-grade gliomas and discusses current challenges facing this patient population that future correlative biology studies combined with advancements in technologies could help overcome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!